Introduction
Although the sextant technique as described in 1989 was long considered the standard for initial prostate biopsy, 1 it has now been shown that the traditional sextant scheme can be associated with significant sampling error, particularly in patients with larger prostate glands. [2] [3] [4] [5] Several recent studies demonstrate that cancer detection can be improved in most cases by obtaining a greater number of biopsies and by directing these additional biopsies more laterally in the prostate. [6] [7] [8] [9] [10] While many urologists are now obtaining more than six samples on initial prostate biopsy, 11 the optimal number of biopsies needed to adequately sample the prostate and to ensure detection of clinically significant cancer is currently unknown. The ability to obtain an increased number of biopsies is often limited by pain and discomfort. Several recent reports advocating the use of periprostatic lidocaine block have demonstrated significantly better patient tolerance with this technique. [12] [13] In a previous study, we reported an outpatient clinic-based extensive biopsy technique using intravenous conscious sedation (IVCS) in men undergoing repeat prostate biopsy.
14 Using this technique in men who had undergone on average 2.1 previous biopsy procedures, a mean of 22.5 biopsy cores were obtained and cancer was detected in 30%. Despite the need for IVCS, many of these men expressed a preference for this technique compared to their previous biopsy procedure because it was associated with much less pain and discomfort. Knowing that patient acceptance of this extensive biopsy technique was high in repeat biopsy patients, we wondered if it could be applied to patients undergoing initial biopsy as well. If this technique resulted in improved detection of clinically significant cancer by allowing more complete prostate sampling, and at the same time allow improved patient acceptance of the biopsy procedure, it might become a feasible option for men presenting for initial prostate biopsy.
The purpose of this study was to investigate the potential role of extensive prostate biopsy utilizing IVCS in men presenting for initial prostate biopsy. We compared this technique to a more standard prostate biopsy as it was being done by the majority of practicing urologists at the beginning of our study (usually obtaining more than six cores utilizing rectal lidocaine gel alone). Our objective was to determine if this extensive biopsy technique resulted in a higher rate of cancer detection and/or improved patient tolerance of the biopsy procedure compared to a more standard biopsy technique.
Methods
Between February 2000 and July 2001, 197 patients ranging in age from 40 to 82 y (mean 61. 2 y) were prospectively randomized to either standard prostate biopsy (6-12 cores obtained) or extensive prostate biopsy (24 cores) using IVCS. The study protocol was approved by our local Institutional Review Board (IRB). Indications for biopsy was an elevated prostate specific antigen (PSA) alone in 104 cases (57%) and an abnormal digital rectal examination with or without elevated PSA in the remainder (43%). PSA was measured using the AxSYM microparticle enzyme immunoassay (Abbott Laboratories, Chicago, IL, USA) and percent free PSA was measured using the PSA II radioimmunoassay (Dianon Laboratories, Connecticut, MA, USA). All patients were given an oral fluoroquinolone antibiotic for three consecutive days beginning one day before the biopsy procedure. Two fleet enemas were administered rectally immediately before the procedure. All biopsies were performed in the clinic setting with the patient in a lateral decubitus position. An ultrasound machine provided guidance with a 7 MHz. bipolar probe, and biopsies were obtained with the prostate imaged in the sagittal plane. An automatic biopsy gun with an 18-gauge needle was used.
A total of 12 different urologists performed the biopsy procedures. For patients randomized to the standard biopsy group, the only anesthetic used was 10 cm 3 of 2% lidocaine gel placed intrarectally 15 min prior to the biopsy procedure. To approximate current biopsy practice and to allow tailoring of biopsy number according to gland size and patient tolerance, the urologist performing the standard biopsy procedure was allowed to determine the number of biopsies to obtain (6) (7) (8) (9) (10) (11) (12) in each patient. In this group, all patients had biopsies taken from the standard sextant locations with additional biopsies directed laterally at the discretion of the urologist performing the biopsy procedure.
All patients in the extensive biopsy group underwent a 24-core biopsy according to a standardized biopsy scheme ( Figure 1 ). Four biopsies each were taken from the sextant (midlobar) and lateral zones bilaterally. In addition, four biopsies on each side were directed more medially, two sampling the peripheral zone and the other two obtained from the transition zone. Thus, a total of four transition zone biopsies were taken in this 24-core scheme. All patients in this group were administered IVCS by a qualified urology clinic nurse. An intravenous line was placed, and patients were placed on cardiac and oxygen saturation monitors during the procedure. Intravenous doses of fentanyl and midazolam were titrated according to individual patient requirement and tolerance. Time from placement of the IV to beginning the biopsy procedure averaged 10 min and the biopsy procedure itself lasted 5-10 min. Following biopsy with IVCS, patients were monitored for approximately 1 h before release from the clinic. These patients were not allowed to drive on the day of the procedure.
Each patient was given a self-administered questionnaire prior to the biopsy that was a modification of the International Prostate Symptom Score (I-PSS) questionnaire. In addition to the seven standard I-PSS questions, four additional questions were asked pertaining to hematuria, hematochezia, hematospermia, and pain in the region of the prostate. The response to each question ranged from 1 to 6, with the higher value conferring worse symptoms. Thus, a total score between 11 and 66 could be obtained from this symptom questionnaire. Patients were asked to repeat the questionnaire responses 1 day, 1 week and 2 weeks after the biopsy procedure. Additionally, on the day after the biopsy, each patient was asked to assess the 'pain you experienced' with the biopsy procedure on a 6-point scale (0-no pain, 1-hardly any pain, 2-minimal pain, 3-some pain, 4-significant pain, 5-much pain and 6-terrible pain) and the 'overall satisfaction' with the biopsy, also on a 6-point scale (0-delighted, 1-pleased, 2-mostly satisfied, 3-mixed, 4-mostly dissatisfied, 5-unhappy and 6-terrible).
Statistical analysis was performed using the STATA 7.0 statistical software program. Potential differences in the prebiopsy characteristics of the standard and extensive biopsy groups (age, PSA, percent free PSA, prostate volume, PSA density and baseline urinary symptom score) were tested using the rank sum test. The clinical stage distribution of these groups was compared using Fisher's exact test. Differences in cancer detection rates were tested for significance using the w 2 -test, and the rank sum test was used to assess differences in urinary symptom score, biopsy pain, and biopsy satisfaction.
Results
A total of 15 patients withdrew from the study leaving a total of 182 patients for analysis. Of these 182 patients, 88 (48%) underwent the standard biopsy (6-12 cores, mean Adenocarcinoma was detected in 73 of 182 patients (40%), with 34 (38.6%) cases in the standard biopsy group, and 39 (41.5%) cases in the extensive group (P ¼ 0.692). Table 2 shows biopsy results for each group. When patients presenting with presumptive cT1c or cT2 stages were analyzed separately, there was still no difference in cancer detection between the standard and extensive biopsy techniques (P ¼ 0.718 and P ¼ 0.813, respectively). The Gleason grade of the cancers found was similarly distributed between the two groups. There was no difference in biopsy yield when cancer detection was analyzed according to gland volume, serum PSA level or patient age. In the extensive biopsy group, two cancers (5%) were detected only in the medially directed peripheral zone biopsies and two others (5%) were detected uniquely in the transition zone.
A total of 164 (90%) patients returned the questionnaires that assessed postbiopsy urinary symptom scores (1 day, 1 week and 2 weeks), perception of 'pain you experienced' and 'overall satisfaction' with the biopsy procedure. Total symptom scores are plotted over time in Figure 2 . As expected, there was an initial increase in the symptom score early after biopsy with a subsequent decline to almost baseline values by 2 weeks. There was no statistical difference in symptom score between groups at any point in time after the biopsy procedure (rank-sum test).
The distribution of pain scores for each biopsy technique is compared in Figure 3 . The extensive biopsy group had significantly lower pain scores (mean 0.9, Figure 2 Urinary symptom scores before and after prostate biopsy comparing the standard and extensive (24-core) biopsy groups. There was no statistical difference in scores between groups at any point in time (P40.05 for all, rank-sum test).
Extensive vs standard prostate biopsy RL Sur et al median 1) compared to the standard (mean 2.6, median 3.0) group (Po0.001). Analysis of the pain score distribution for the extensive biopsy group showed that 72% rated the pain as 0 or 1 (0 ¼ 'no pain' and 1 ¼ 'hardly any pain.') In contrast, only 25% of the standard biopsy patient rated pain a 0 or 1 ( Figure 3) . A comparison of satisfaction with the biopsy procedure also demonstrated a significant advantage (po0.001) for the extensive vs the standard biopsy group (mean score 0.8 vs 1.6, respectively). Satisfaction score distribution for each group is compared in Figure 4 . While 81% of the extensive biopsy group was either 'delighted' (score 0) or pleased (score 1) with the procedure, only 52% of the standard biopsy group had similarly low scores. There were no complications associated with the biopsy procedure in those undergoing standard biopsy. Four patients (4%) in the extensive biopsy group developed urinary retention requiring urethral catheter placement for 24 h. One patient developed atrial fibrillation during the extensive biopsy procedure that required cardioversion later that day with no further sequelae. There was no significant rectal bleeding or hematuria in either group and no patient developed urosepsis or prostatitis. Extensive vs standard prostate biopsy RL Sur et al
Discussion
Numerous recent investigations have shown that standard sextant biopsy as originally described by Hodge et al 1 provides inadequate prostate sampling, leaving as many as 30% of cancers undetected. [2] [3] [4] To limit this sampling error, more extensive biopsy schemes are now being more commonly utilized. [6] [7] [8] [9] [10] One of the first extended biopsy schemes was proposed by Eskew et al 6 who described a 5-region, 13-core, biopsy strategy that increased cancer yield by 35% with the addition far lateral and midline sagittal biopsies. In a prospective study of 483 consecutive initial biopsy patients, Presti et al 7 investigated the utility of a 10-core biopsy scheme, showing that sextant biopsies alone would have missed 20% of cancers detected. They proposed a minimum 8-core biopsy scheme to maximize cancer detection. Another recent large retrospective study assessed the yield of a 12-core biopsy scheme in 2299 patients biopsied by 167 community-based urologists. 10 In this study, sextant biopsy alone would have left 22% of cancers undetected. While it is clear from these and other studies that the optimal scheme for initial prostate biopsy should include more than six core samples, the optimal number of biopsies required to maximize cancer detection without over detection of clinically insignificant cancers is still uncertain. We and others have described an extensive or 'saturation' biopsy technique for men undergoing repeat prostate biopsy in the face of multiple previous negative biopsies and the persistence of suspicious clinical and/or pathological findings (elevated PSA, increased PSA velocity or previous finding of HGPIN or ASAP). 14, 15 In the Mayo Clinic series reported by Stewart et al, 15 general or spinal anesthesia was used to obtain on average 23 biopsy cores with a 34% overall cancer detection rate. In our previously reported series utilizing a similar extensive biopsy scheme in 57 repeat biopsy patients, IVCS in the outpatient clinic setting was used to obtain an average of 22.5 cores with a very similar cancer detection rate of 30%.
14 Notably, of the patients in this series who had undergone radical prostatectomy, 92% were determined to have clinically significant cancer as measured by tumor volume and grade, suggesting that extensive biopsy does not detect an inordinate number of insignificant cancers. In our experience with this biopsy technique, there were two other advantages that were apparent. First, we noted great patient acceptance of this anesthetic method. All patients in this series had undergone several previous standard biopsies with the use of rectal lidocaine jelly alone and almost all preferred the technique using IVCS. Secondly, by obtaining a large number of biopsy cores and essentially eliminating the possibility of sampling error, we could confidently reassure patients with negative biopsies and advise them that no further biopsies were necessary.
In the present study, this extensive biopsy scheme was investigated as an initial biopsy procedure. To our surprise, cancer detection was no greater with this 24-core biopsy technique compared to a standard extended biopsy technique in which an average of 10 core samples were obtained. One theoretical advantage of a saturation biopsy technique might be improved cancer detection in larger glands due to decreased sampling error. However, cancer detection with extensive biopsy was not better than standard biopsy for glands greater than 40 g in our series. Extensive and standard biopsy also resulted in similar cancer detection rates in patients with lower PSA levels and nonpalpable disease, where more extensive prostate sampling might be expected to more readily detect small volume cancers. While it is uncertain why our extensive biopsy scheme did not increase cancer detection, it is important to realize that it was not compared to a standard sextant scheme in which case it almost certainly would have been found to be superior. Rather, 'standard' biopsy patients in our series were getting an extended biopsy procedure that has been shown in other series to be associated with increased cancer detection. 7, 10 Almost all patients (94%) in our standard biopsy group had laterally directed biopsies and 81 of 88 (92%) had eight or more biopsies taken. Although the strength of our conclusions are limited to some degree by our relatively small sample size, the results imply that 'saturation' biopsy is not necessary in patients undergoing initial prostate biopsy as long as an extended biopsy scheme of 8-12 cores is utilized. Perhaps for initial biopsy, lateral direction of the biopsies is more important than biopsy number itself in maximizing cancer detection.
While rectal lidocaine gel alone was a standard method for local anesthesia when our study was initiated, some reports have now shown that local anesthetic with periprostatic lidocaine injection decreases pain and improves tolerance of the biopsy procedure. 12, 13 One recent study comparing rectal lidocaine gel to placebo (lubricant gel) found no benefit in pain control with the lidocaine. 16 Thus, it is not surprising that IVCS was far superior to rectal lidocaine gel in terms of pain and patient satisfaction, despite a far greater number of cores being obtained. During IVCS both narcotic (fentanyl) and amnestic (midazolam) agents are used. It is likely that the memory of the biopsy procedure was as important to patient perception as the pain or discomfort itself. Although not included as part of our questionnaire, most patients receiving IVCS reported minimal recollection of the actual probe insertion and biopsies. We surmise that poor recall of the procedure may have contributed to the perception of no pain in 40% of the IVCS group and the very high satisfaction with this technique. While patients clearly prefer this method of anesthesia over rectal lidocaine gel alone, we do not know how IVCS compares to the current practice of periprostatic lidocaine block. These two techniques are currently being compared in an ongoing study at our institution.
Urinary symptom scores were not higher in the extensive biopsy group. In both groups, symptom scores rose from baseline after biopsy as expected but then dropped to baseline within 2 weeks. This finding differs from that of Naughton et al 17 who found a significantly higher rate of hematuria and hematochezia when increasing biopsy number from 6 to only 12 cores. In Eskew et al's original report of a five-region biopsy scheme, midline biopsies involving the urethra were associated with the development of significant postbiopsy hematuria. Since we avoid midline biopsies with our extensive biopsy scheme, we have not found hematuria to be a significant problem and significant rectal bleeding is rare. However, as noted in our previous study using the extensive biopsy technique, a small Extensive vs standard prostate biopsy RL Sur et al number (4%) of patients develop urinary retention after extensive prostate biopsy. All were managed successfully with a urinary catheter that was removed in all cases within 24 h. It is unknown whether this postbiopsy urinary retention is the result of temporary prostatic edema induced by extensive biopsy, the intravenous medications administered or a combination of these two factors.
Our study has several limitations. Although biopsy number and location were standardized in the extensive, 24-core biopsy group, the standard biopsies were performed by multiple urologists who obtained variable numbers of biopsy samples depending on factors such as prostate size and patient tolerance. While core location and number may have affected biopsy yield in the standard biopsy group, we thought it important to allow some tailoring of the biopsy procedure in order to accurately compare our extensive technique to what was currently practiced by urologists in the community. It is also possible that contact with our clinic nurse before and after IVCS may have biased the patient's perception of pain and satisfaction in favor of the extensive technique. There may also be subgroups of patients in which our extensive biopsy may result in superior cancer detection that was not demonstrated statistically due to the limited total number of biopsy patients enrolled. Despite these limitations, however, our study suggests that although much better tolerated, extensive 24-core biopsy is not necessary as an initial biopsy procedure.
Conclusions
Extensive prostate biopsy with 24 cores utilizing IVCS does not improve cancer detection rates compared to a standard biopsy technique in which an average of 10 core samples are obtained. The IVCS technique is very well tolerated and associated with significantly less pain and greater patient satisfaction than rectal lidocaine gel alone.
